Lord, Abbett & Co
CAI

Lord, Abbett & Co’s Caris Life Sciences CAI Stock Holding History

Lord, Abbett & Co’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-850,000
Closed -$25.7M – 614
2025
Q3 		$25.7M Buy
+850,000
New +$27.1M 0.08% 251

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lord, Abbett & Co's CAI Position: Q4 2025 in Review

Lord, Abbett & Co sold out of Caris Life Sciences (CAI) in Q4 2025, closing a stake of 850,000 shares — an estimated $25.7M sold.

Lord, Abbett & Co first reported a position in CAI in Q3 2025 and held it in 1 quarter. The position peaked at $25.7M in Q3 2025. 186 funds tracked by Wall St. Rank hold CAI as of Q4 2025.

  • Lord, Abbett & Co reported no remaining Caris Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 850,000 Caris Life Sciences shares in Q4 2025, an estimated $25.7M.
  • Lord, Abbett & Co first reported a position in Caris Life Sciences in Q3 2025 and held it in 1 quarter.
  • Lord, Abbett & Co's Caris Life Sciences position peaked at $25.7M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Caris Life Sciences as of Q4 2025.

Based on Lord, Abbett & Co's 13F filing for Q4 2025, filed 13 Feb 2026.